This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haskey, N. Articles by Dahl, W. J. Search for Related Content Social Bookmarking                         What's this?

Synbiotic Therapy Improves Quality of Life and Reduces Symptoms in Pediatric Ulcerative Colitis

Saskatoon Health Region, Saskatoon, Saskatchewan, Canada

Wendy J. Dahl, PhD, RD

Food Science and Human Nutrition Department, University of Florida, Gainesville, wdahl{at}ufl.edu, Institut Rosell (Montreal, QC, Canada) and Sensus America LLC (Monmouth Junction, New Jersey)

The management of ulcerative colitis in children often requires aggressive pharmacological therapy or colonic resection. The authors hypothesized that synbiotic therapy would improve symptoms and quality of life in children diagnosed with ulcerative colitis. Pediatric study participants (8-18 years; n = 9) with ulcerative colitis in remission were provided synbiotic therapy (Bifidobacterium longum R0175 20 billion cfu/d, 15 g/d of inulin; n = 4) or placebo (maltodextrin + ascorbic acid capsule; 15 g/d of non-resistant maltodextrin; n = 5) for 10 months in a pilot study (phase I). At 10 months, the study was unblinded and synbiotic therapy was administered to 8 pediatric study participants (phase II). Quality of life was measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ was administered at baseline and every 2 months. Study participants kept a daily record of symptoms. Phase I quality-of-life scores were significantly better for those receiving the synbiotic therapy versus the placebo (P = .014). Severe symptoms occurred in 60% of the control study participants, whereas no study participants receiving synbiotic therapy experienced severe symptoms (P = .032). Phase II quality-of-life scores were significantly better posttreatment with synbiotic therapy (P = .034). No adverse effects were reported. Synbiotic therapy (B longum R0175 + inulin), when provided in addition to conventional treatment, appears to be a safe and effective strategy for managing pediatric ulcerative colitis in remission.

Key Words: adolescent/teen • early life span nutrition • pre- and probiotic therapy • gastrointestinal disorders

ICAN: Infant, Child, & Adolescent Nutrition, Vol. 1, No. 2, 88-93 (2009)
DOI: 10.1177/1941406409332930


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?